Breaking News, Trials & Filings

SK bioscience COVID-19 Vaccine Granted Emergency Use by WHO

SKYCovione induced neutralizing antibody responses against SARS-CoV-2 parental strain and had a standard safety and reactogenicity profile.

SK bioscience, a global innovative vaccine and biotech company, has received the WHO Emergency Use Listing (EUL) of its COVID-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for SARS-CoV-2. The vaccine was developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine and uses GSK’s pandemic adjuvant. SKYCovione is also the world’s first me...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters